Literature DB >> 7658435

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

G W Rewcastle1, W A Denny, A J Bridges, H Zhou, D R Cody, A McMichael, D W Fry.   

Abstract

A series of 4-substituted quinazolines and related compounds have been prepared and evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor receptor on a phospholipase C-gamma 1-derived substrate. The results show a narrow structure-activity relationship (SAR) for the basic ring system, with quinazoline being the preferred chromophore and benzylamino and anilino the preferred side chains. In the 4-anilino series, substitution on the 3-position of the phenyl ring with small lipophilic electron-withdrawing groups provided analogues with enhanced potency. Two series of compounds [4-(phenylmethyl)amino and 4-(3-bromophenyl)amino] were studied to determine SARs for quinazoline substituents. In the more active 4-(3-bromophenyl)amino series, electron-donating groups (NH2, OMe) at the 6- or 7-position increased activity, in a pattern consistent with a requirement for high electron density in the vicinity of the 8-position of the quinazoline ring. The 6,7-dimethoxy derivatives were the most effective in both series, with the 4-(3-bromophenyl)amino derivative (3) having an IC50 of 0.029 nM, making it by far the most potent reported inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658435     DOI: 10.1021/jm00018a008

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.

Authors:  Meaghan MacPhee; Zakaria Rachid; Margarita Todorova; Qiyu Qiu; Gina Belinsky; Bertrand J Jean-Claude
Journal:  Invest New Drugs       Date:  2010-04-29       Impact factor: 3.850

2.  Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.

Authors:  Xiaoqing Wu; Mingdong Li; Yang Qu; Wenhua Tang; Youguang Zheng; Jiqin Lian; Min Ji; Liang Xu
Journal:  Bioorg Med Chem       Date:  2010-04-21       Impact factor: 3.641

3.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization.

Authors:  Julien Michel; Julian Tirado-Rives; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

4.  Quantitative prediction of fold resistance for inhibitors of EGFR.

Authors:  Trent E Balius; Robert C Rizzo
Journal:  Biochemistry       Date:  2009-09-08       Impact factor: 3.162

Review 5.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

6.  N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs
Journal:  Bioorg Med Chem       Date:  2013-01-10       Impact factor: 3.641

Review 7.  HER-2-directed, small-molecule antagonists.

Authors:  Michelle Arkin; Mark M Moasser
Journal:  Curr Opin Investig Drugs       Date:  2008-12

8.  Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.

Authors:  Saw Simeon; Nathjanan Jongkon; Warot Chotpatiwetchkul; M Paul Gleeson
Journal:  J Comput Aided Mol Des       Date:  2019-09-07       Impact factor: 3.686

9.  3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Authors:  Haregewein Assefa; Shantaram Kamath; John K Buolamwini
Journal:  J Comput Aided Mol Des       Date:  2003-08       Impact factor: 3.686

10.  A fluorescent reporter of ATP binding-competent receptor kinases.

Authors:  Renaud Sicard; Jyothi Dhuguru; Wenjun Liu; Nirav Patel; Ralf Landgraf; James N Wilson
Journal:  Bioorg Med Chem Lett       Date:  2012-07-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.